SILAC-Based Quantitative Proteomic Analysis of Diffuse Large B-Cell Lymphoma Patients. (28th April 2015)

• Record Type: Journal Article
• Authors: Rüetschi, Ulla; Stenson, Martin; Hasselblom, Sverker; Nilsson-Ehle, Herman; Hansson, Ulrika; Fagman, Henrik; Andersson, Per-Ola
• Other Names: Christopherson Richard Academic Editor.
• Is Part Of: International journal of proteomics. Volume 2015(2015)
• Publication Date: 2015-04-28
• Subjects: Proteomics -- Periodicals; Proteomics; Proteomics; Electronic journals; Periodical; Fulltext; Internet Resources; Periodicals; Periodicals; 572.6
• DOI: 10.1155/2015/841769
• Languages: English
• ISSNs: 2090-2166

Abstract

Abstract : Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma, is a heterogeneous disease where the outcome for patients with early relapse or refractory disease is very poor, even in the era of immunochemotherapy. In order to describe possible differences in global protein expression and network patterns, we performed a SILAC-based shotgun (LC-MS/MS) quantitative proteomic analysis in fresh-frozen tumor tissue from two groups of DLBCL patients with totally different clinical outcome: (i) early relapsed or refractory and (ii) long-term progression-free patients. We could identify over 3, 500 proteins; more than 1, 300 were quantified in all patients and 87 were significantly differentially expressed. By functional annotation analysis on the 66 proteins overexpressed in the progression-free patient group, we found an enrichment of proteins involved in the regulation and organization of the actin cytoskeleton. Also, five proteins from actin cytoskeleton regulation, applied in a supervised regression analysis, could discriminate the two patient groups. In conclusion, SILAC-based shotgun quantitative proteomic analysis appears to be a powerful tool to explore the proteome in DLBCL tumor tissue. Also, as progression-free patients had a higher expression of proteins involved in the actin cytoskeleton protein network, such a pattern indicates a functional role in the sustained response to immunochemotherapy.